|
Delayed
Sao Paulo
09:47:04 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 9.050 BRL | -1.09% |
|
+4.02% | -56.70% |
| 10-19 | Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi | MT |
| 10-14 | Ultragenyx Pharmaceutical to Sell Priority Review Voucher for $203 Million | DJ |
Stock exchange
Sao Paulo
R2AR34 9.050 R$
-1.09%
461.55
R$
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
| RARE | 16.18USD | -3.58% | 3.43M $ | ||
CBOE
| RARE | 16.17USD | -3.61% | 95.37K $ | |
|
Tradegate
| UP0 | 14.93EUR | -0.67% | 2.99K € | |
|
Berne S.E.
| UP0 | 10.76CHF | -16.55% | 1.61K CHF | |
|
Mexican S.E.
| RARE * | 256.00MXN | +0.47% | 4.1K $ | |
|
Boerse Muenchen
| UP0 | 14.56EUR | -2.67% | 145.55 € | |
|
Deutsche Boerse AG
| UP0 | 14.92EUR | -2.55% | 0 € | |
|
Börse Stuttgart
| UP0 | 14.53EUR | -2.58% | 0 € | |
|
Xetra
| UP0 | 14.81EUR | -3.30% | 0 € | |
| R2AR34 | 9.050BRL | -1.09% | 461.55 R$ |
Quotes 5-day view: Ultragenyx Pharmaceutical Inc.
Delayed Quote Sao Paulo
| 2026-10-26 | 2026-10-27 | 2026-10-28 | 2026-10-29 | 2026-10-30 | |
|---|---|---|---|---|---|
| Last | R$8.700 | R$8.840 | R$9.230 | R$9.150 | R$9.050 |
| Volume | 420 | 124 | 1,531 | 20 | 51 |
| Change | +21.17% | +1.61% | +4.41% | -0.87% | -1.09% |
| Opening | R$8.590 | R$8.700 | R$8.660 | R$9.330 | R$9.040 |
| High | R$8.700 | R$8.840 | R$9.260 | R$9.420 | R$9.050 |
| Low | R$8.590 | R$8.580 | R$8.660 | R$9.150 | R$9.040 |
Performance
| 1 day | -1.09% | ||
| 1 week | +4.02% | ||
| Current month | +21.15% | ||
| 1 month | +13.27% | ||
| 3 months | -27.83% | ||
| 6 months | -23.76% | ||
| Current year | -56.70% | ||
| 1 year | -54.52% | ||
| 3 years | -52.64% |
Volumes
marketsDaily volume
51
Estimated daily volume
254
Avg. Volume 20 sessions
373
Daily volume ratio
0.68
Avg. Volume 20 sessions BRL
3,375.65
Avg. Volume 20 sessions USD
623.27
Record volume 1
18,070
Record volume 2
18,000
Record volume 3
10,367
Capital turnover ratio
0
Float rotation
0
Basic data
Market Cap (BRL)
1,649,287,288
Market Cap (USD)
1,649,287,288
Net sales (USD)
673,000,000
Number of employees
1,371
Sales / Employee (USD)
490,883
Free-Float
96.28%
Free-Float capitalization (BRL)
295,158,327
Free-Float capitalization (USD)
1,597,544,446
Average Daily Capital Traded
-.--%
Indicators
Moving average 5 days
8.98
Moving average 20 days
7.741
Moving average 50 days
10.17
Moving average 100 days
10.19
Price spread / (MMA5)
-0.77%
Price spread / (MMA20)
-14.46%
Price spread / (MMA50)
+12.40%
Price spread / (MMA100)
+12.57%
STIM
RSI 9 days
70.82
RSI 14 days
59.56
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.09% | +4.02% | -54.52% | -52.64% | 1.65B | |
| +4.00% | +11.75% | +68.52% | +151.57% | 1,224B | |
| +0.69% | +5.25% | +46.87% | +88.84% | 662B | |
| +1.33% | +3.03% | +28.97% | +107.41% | 514B | |
| +0.11% | +2.71% | +53.42% | +66.39% | 388B | |
| +1.19% | +2.36% | +72.35% | +44.82% | 361B | |
| +1.28% | +4.69% | +35.52% | +58.34% | 302B | |
| +6.05% | +7.86% | +10.25% | +35.37% | 271B | |
| +1.90% | +7.02% | +60.99% | +78.61% | 249B | |
| +3.06% | +10.35% | +45.38% | +121.41% | 205B | |
| Average | +1.68% | +2.59% | +36.77% | +70.01% | 417.85B | |
| Weighted average by Cap. | +2.17% | +3.04% | +51.35% | +98.87% |
Historical Quotes: Ultragenyx Pharmaceutical Inc.
| Date | Opening | High | Low | Close | Volume | Change |
|---|
Latest transactions
d6871.xDfFYV2r00L-gdqlksBm6tWNWH7Fz1j_9vho7-qSCBc.93GiDjGdsQiE0pmdyIUkrpLsPgSkuDewl6c4toLTZnaSZLMSbMKGMZK4gw
| Date | Price | Volume | Total |
|---|---|---|---|
| 09:47:04 | 9.050 | 1 | 51 |
Price Extremes
| 1 week | 8.58 |  | 9.42 |
| 1 month | 7.07 | | 9.42 |
| Current year | 6.68 | | 18.64 |
| 1 year | 6.68 | | 20.9 |
| 3 years | 6.68 | | 33.03 |
| 5 years | 6.68 | | 39.36 |
| 10 years | 6.68 | | 39.36 |
Monthly variations
Annual variations
| 2026 | -56.22% | ||
| 2025 | -31.63% | ||
| 2024 | +35.03% | ||
| 2023 | -15.05% | ||
| 2022 | -27.95% |
- Stock Market
- Stocks
- RARE Stock
- R2AR34 Stock
- Quotes Ultragenyx Pharmaceutical Inc.
Select your edition
All financial news and data tailored to specific country editions
